Maze Therapeutics appointed Paula A. Johnson as a Class III director and Sophie Kornowski as a Class I director effective August 13, 2026. Dr. Johnson receives a $40,000 annual cash retainer pro-rated for the remainder of the year plus committee retainers and an option to purchase 36,000 shares vesting monthly. Dr. Kornowski receives identical compensation terms. The Board also adjusted board class composition by reappointing Nancy C. Andrews from Class III to Class II and Hervé Hoppenot from Class II to Class III to maintain equal distribution among the three classes. Maze Therapeutics operates in the biopharmaceutical industry, developing targeted therapies for cancer.

Maze Therapeutics reported financial results for the second quarter ended June 30, 2026. The company recognized $20.0 million in license revenue from a milestone achievement under its agreement with Shionogi & Co., Ltd. for MZE001. R&D expenses increased to $34.9 million and G&A expenses rose to $13.1 million, resulting in a net loss of $44.7 million, or $0.76 per share. Cash, cash equivalents, and marketable securities totaled $495 million as of June 30, 2026, providing an expected cash runway into 2029. Clinically, the Phase 2 CIPheR trial of MZE782 in PKU is ongoing with topline data expected in 2027, while enrollment in the Phase 2 HORIZON trial of MZE829 for APOL1-mediated kidney disease continues across three cohorts. Maze plans to initiate a pivotal trial for MZE829 in the first half of 2027 and a Phase 2 CKD trial for MZE782 in early 2027. Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases.